Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer
The purpose of this study was to evaluate the efficacy and safety of docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC). Thirty-four patients with advanced NSCLC received docetaxel 75 mg/m2 (1-h intravenous infusion) every 3 weeks, with corticosteroid premedication...
Saved in:
| Main Authors: | , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
2014
|
| 在線閱讀: | http://www.scopus.com/inward/record.url?eid=2-s2.0-0036985870&partnerID=40&md5=c9ee0ff44844ea8301aa32e0149fdcbf http://www.ncbi.nlm.nih.gov/pubmed/12678167 http://cmuir.cmu.ac.th/handle/6653943832/2100 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|